Stephen Tilley, MD
Pulmonary Disease · Chapel Hill, NCNPI 1437210465
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.1%), consulting fees and education — rather than concentrated in one kind of arrangement. GSK accounts for 69.1% of it on its own, with 7 other manufacturers making up the rest. That places this record below the midpoint for pulmonary disease clinicians in NC, where the typical reported total is $1,396.
Across 36 payments — averaging $34.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$861
- Viatris Specialty LLC$139
- Mylan Specialty L.p.$83
- Mallinckrodt Hospital Products Inc.$75
- Astrazeneca UK Limited$33
- AstraZeneca$22
- plus $34 from 2 others
Across 48 payments — averaging $7557.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$336K
- GSK$16K
- Teva Pharmaceuticals USA, Inc.$11K
What the payments were for
- Consulting fees$46037%
- Food & beverage$69956%
- Education$877%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $861 |
| Viatris Specialty LLC | 3 | $139 |
| Mylan Specialty L.p. | 3 | $83 |
| Mallinckrodt Hospital Products Inc. | 1 | $75 |
| Astrazeneca UK Limited | 1 | $33 |
| AstraZeneca | 1 | $22 |
| Sanofi | 1 | $22 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADVAIR$460
- Yupelri$102
How this compares
$1,247 in reported general payments places this provider in the 45th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 292 | $266,022 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 140 | $120,362 |
| XolairOmalizumab | 16 | $54,290 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 53 | $30,117 |
| SymbicortBudesonide/Formoterol Fumarate | 117 | $29,590 |
| Spiriva RespimatTiotropium Bromide | 42 | $26,934 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $22,560 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 24 | $15,041 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 49 | $14,010 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $13,980 |
| Atrovent HfaIpratropium Bromide | 16 | $11,812 |
| EliquisApixaban | 12 | $11,397 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $11,000 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $8,019 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $861 | $328,902412 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $22 | $169,393292 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Chapel Hill
- James DonohueChapel Hill$271K
- Hubert FordChapel Hill$94K
- Scott DonaldsonChapel Hill$47K
- Michael KnowlesChapel Hill$36K
- Mary DanielsChapel Hill$15K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- Eric MeltzerDurham$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.